Everything below concerns GLP-1 receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-24. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
=== Competition with other platforms === Although the size of its user base falls short of that of Facebook, Instagram, or YouTube, TikTok reached 1 billion active monthly users faster than any of them. Competition from TikTok prompted Instagram, which is owned by Facebook, to spend $120 million as of 2022 to entice more content creators to its Reels service, although engagement level remained low. Snapchat had likewise paid out $250 million in 2021 to its creators. Many platforms and services, including YouTube Shorts, began to imitate TikTok's format and recommendation page. Those changes caused a backlash from users of Instagram, Spotify, and Twitter. In March 2022, The Washington Post reported that Facebook's owner Meta Platforms paid Targeted Victory—a consulting firm backed by supporters of the US Republican Party—to coordinate lobbying and media campaigns against TikTok and portray it as "a danger to American children and society". Its efforts included asking local reporters to serve as "back channels" of anti-TikTok messages, writing opinion articles and letters to the editor, including one in the name of a concerned parent, amplifying stories about TikTok trends, such as "devious licks" and "Slap a Teacher", that actually originated on Facebook, and promoting Facebook's own corporate initiatives. Ties to Meta were not disclosed to the other parties involved. Targeted Victory said that it is "proud of the work". A Meta spokesperson said that all platforms, including TikTok, should face scrutiny.
== Contraindications == Contraindications of progesterone include hypersensitivity to progesterone or progestogens, prevention of cardiovascular disease (a Black Box warning), thrombophlebitis, thromboembolic disorder, cerebral hemorrhage, impaired liver function or disease, breast cancer, reproductive organ cancers, undiagnosed vaginal bleeding, missed menstruations, miscarriage, or a history of these conditions. Progesterone should be used with caution in people with conditions that may be adversely affected by fluid retention such as epilepsy, migraine headaches, asthma, cardiac dysfunction, and renal dysfunction. It should also be used with caution in patients with anemia, diabetes mellitus, a history of depression, previous ectopic pregnancy, and unresolved abnormal Pap smear. Use of progesterone is not recommended during pregnancy and breastfeeding. However, the medication has been deemed usually safe in breastfeeding by the American Academy of Pediatrics, but should not be used during the first four months of pregnancy. Some progesterone formulations contain benzyl alcohol, and this may cause a potentially fatal "gasping syndrome" if given to premature infants.
The city was procuring only electric buses as of 2021, gradually replacing the diesel bus fleet. Moscow was expected to become the leading European city in its share of electric versus gas fuel in public transit by 2019.
Cell Centered Database – Astrocyte UIUC Histology Subject 57 "Astrocytes" Archived 2012-11-21 at the Wayback Machine at Society for Neuroscience The Department of Neuroscience at Wikiversity NIF Search – Astrocyte via the Neuroscience Information Framework
Sources: en.wikipedia.org
=== Progression === 30–40% of UCTD cases may develop into a defined connective tissue disease as more diagnostic criteria are progressively met. This generally happens within five years of onset. Several factors may help predict progression:
=== Psychological profile === Prior to the trial, the court ordered further psychological assessment for Agüero. The evaluating professionals determined that Agüero has a "self-centered personality", and that she seeks "recognition, power, and admiration", plus "lack of empathy and affection, with expressions of satisfaction from close contact with another person's suffering". The mental health professionals also found that Agüero has traits of a dissociative personality disorder, with one side of her personality being completely aware of reality, while the other side denies said reality and compensates for it with the production of her wishes. The same professionals stated that these traits are "typical mechanisms of a psychopathic personality". During the trial, further testimony was presented by mental health professionals. Psychologist Martínez Goyena said that Agüero does not suffer from any active mental health disorder, and that she is capable of understanding reality. Further analysis showed narcissistic, self-referential, and psychopathic traits. Defense psychiatrist Quiroga said, in contrast, that there are no previous indicators that Agüero could have psychopathic features in her personality. Multiple mental health professionals testified on 18 February that Agüero seeks "visibility" for her crimes, as well as repeating pre-trial examination findings that she lacks empathy, citing the total reluctance by Agüero to acknowledge the suffering of the families of the murdered babies.
== History == In October 1967, Techtron Pty Ltd merged with Varian Associates. Techtron is a manufacturer of Atomic Absorption Spectrometers and Spectral lamps. In 1982, Varian transferred the Cary UV-Visible product line to Australia. In 1997, Varian bought Chemagnetics, a Colorado-based manufacturer of solid-state NMR spectrometers. In 2002, Varian bought Ansys Technologies, Inc., a California-based manufacturer of In-Vitro Medical Devices. In 2004, Varian Inc bought Magnex Scientific, an Oxford-based manufacturer of high-field magnets. In 2005, Varian bought Polymer Laboratories, a speciality polymer analysis and manufacturing company. In 2006, Varian bought Ion Spec, an FTMS (Fourier Transform Mass Spectrometry) manufacturing company. In 2007, Varian, Inc. bought Analogix, Inc., a company specializing in flash chromatography. In 2008, Varian bought Oxford Diffraction, a British company specializing in X-ray diffraction equipment. On 27 July 2009, Agilent Technologies announced it would buy Varian Inc, for $1.5 Billion. On 14 October 2014, Agilent made the strategic decision to close its NMR business. Agilent entered the NMR business in 2010, with the acquisition of Varian. Several former Varian engineers have continued the business through private ventures, including the probe department spawning the company PhoenixNMR and the software being made open source.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Long-term storage is usually at minus 20 to minus 80 degrees Celsius in a sealed, desiccated container. Working aliquots can be held briefly at 2 to 8 degrees Celsius.